

To: P128094 (2042373468) - MS. SUSAN T LESSARD-FRIESEN (R2425B)
From: PTM on behalf of ASTRAZENECA CANADA INC
For change of address; fax number or transmission difficulties please reply to fax 1-888-490-4660



Dear Healthcare Professional,

On behalf of everyone at AstraZeneca Canada, thank you for your tireless efforts on the frontlines, helping to support the health of Canadians through this devastating pandemic. We want to take this opportunity to provide an update on important recent developments related to *AstraZeneca COVID-19 Vaccine* and highlight resources available to Canadians and healthcare practitioners.

As background, Health Canada (<https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/75389a-eng.php>) recently completed their ongoing safety review of the *AstraZeneca COVID-19 Vaccine*, concluding that very rare reports of blood clots associated with low levels of blood platelets (i.e., combination of thrombosis and thrombocytopenia) may be associated with our vaccine. They indicated that "the safety of the AstraZeneca vaccine meets its strict safety standards and the Department is adjusting the product's labelling to reflect the available scientific evidence. The potential risk of these events is very rare, and the benefits of the vaccine in protecting against COVID-19 outweigh its potential risks."

Patient safety remains our highest priority, and it always will. We have been collaborating and continue to work closely with Health Canada and healthcare practitioners to define the nature of these extremely rare blood clot events. We also continue to work closely with Health Canada to monitor all adverse events from around the world and provide up-to-date information on our vaccine to ensure Canadian healthcare practitioners and patients receive accurate guidance and understand the benefits and risks.


We recognize many Canadians may have questions, even concerns, about the risk of blood clots following immunization with our vaccine. You will find a number of different resources on the *AstraZeneca COVID-19 Vaccine* website (<https://www.azcovid-19.com>) and Health Canada's COVID-19 resources website (<https://covid-vaccine.canada.ca/astrazeneca-covid-19-vaccine/product-details>) to help support you in discussions with patients.

Beginning April 28th, AstraZeneca Canada is introducing a series of educational webinars – *Practical Guide to COVID-19 Immunization* – for all Canadian healthcare practitioners, where you will have the opportunity to review and discuss the latest Health Canada information, National Advisory Committee on Immunization (NACI) recommendations, and evidence surrounding all of the Canadian-approved COVID-19 vaccines (<https://covid19-immunization-learning-program-2021.ca>).

To change the course of the pandemic, COVID-19 vaccines need to be available globally and accessible to all who need them. In Canada, we are working very diligently with the Public Health Agency of Canada (PHAC) to expedite the delivery of vaccines for Canadians. We also remain focused on delivering on a commitment we have made to make the vaccine available broadly and equitably, at no profit during the pandemic, to people around the world.

Healthcare practitioners can reach out to AstraZeneca's Medical Information Department at ASK-Medical@astrazeneca.com with any inquiries. Thank you again – we are incredibly grateful for your unwavering leadership and personal sacrifices throughout this challenging period.

Best regards,



Neil Maresky
Vice President, Scientific Affairs
AstraZeneca Canada